Craft

Isofol Medical

Stock Price

KR3.7

2024-10-29

Market Capitalization

KR609.7 M

2024-10-29

Isofol Medical Summary

Company Summary

Overview
Isofol Medical is a biotech company that focuses on a cancer drug. It develops Arfolitixorin to treat colorectal cancer. Arfolitixorin can potentially be used as a therapy after high-dose chemotherapy with methotrexate in conjunction with osteosarcoma (bone cancer) and as the treatment of pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers.
Type
Public
Status
Active
Founded
2008
HQ
Gothenburg, SE | view all locations
Website
https://isofolmedical.com
Cybersecurity rating
Sectors

Key People

  • Karin Gedda

    Karin Gedda, Director Clinical Operations

    • Ulf Jungnelius

      Ulf Jungnelius, Chief Executive Officer

      • Aram Mangasarian

        Aram Mangasarian, Board Member

        • Roger Tell

          Roger Tell, Chief Scientific Officer and Chief Medical Officer

          LocationsView all

          1 location detected

          • Gothenburg, Västra Götalands län HQ

            Sweden

            Biotech Center, Arvid Wallgrens Backe 20

          Isofol Medical Financials

          Summary Financials

          Gross profit (Q1, 2026)
          kr159.0K
          Net income (Q1, 2026)
          (kr15.1M)
          Cash (Q1, 2026)
          kr55.7M
          EBIT (Q1, 2026)
          (kr15.6M)

          Footer menu